SUGAR: resultats d'une etude observationnelle belge concernant l'utilisation de la sitagliptine chez des patients diabetiques de type 2. ; Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes

peer reviewed ; Sitagliptin (Januvia), the first selective inhibitor of dipeptidylpeptidase-4, has been assessed in a large Belgian prospective observational study. The aim of the SUGAR study was to evaluate the efficacy of sitagliptin, at a dose of 100 mg once daily, when it was added in patients with uncontrolled type 2 diabetes followed in real life conditions. In the intent-to-treat population (n = 605), mean glycated haemoglobin level decreased from 8.41 +/- 1.18% to 7.29 +/- 0.86% after a follow up averaging 110 days (p < 0.0001). Similarly, mean fasting plasma glucose level decreased... Mehr ...